A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis

NCT07237568

Status	RECRUITING
Phase	Phase 3
Sponsor	Lynk Pharmaceuticals Co., Ltd
Enrollment	352 participants

Key Eligibility Criteria

Inclusion (3)

- Must have a clinical diagnosis of ankylosing spondylitis (AS) and meet the modified New York Criteria for AS.
- Participant must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score e 4 at the Screening and Baseline Visits and Must have a Total Back Pain score e 4 based on a 0 - 10 numerical rating scale at the Screening and Baseline Visits.
- Has had an inadequate response to at least 2 nonsteroidal anti-inflammatory drugs (NSAIDs) over an at least 4-week period in total at maximum recommended or tolerated doses, or has an intolerance to or contraindication for NSAIDs as defined by the Investigator.

Exclusion (4)

- Total spinal ankylosis.
- Participants with known allergies to components or excipients of the study drug.
- Requirement of prohibited medications during the study.
- Participants who are pregnant, nursing, or planning a pregnancy during the study period.

Locations (1 total)

Peking Union Medical College Hospital, Beijing, China